Selim Isbir C, Doğan R, Farsak B, Aydin M, Kilinç K
Department of Cardiovascular Surgery, Marmara University Hospital, Istanbul, Turkey.
Cell Biochem Funct. 2000 Jun;18(2):85-91. doi: 10.1002/(SICI)1099-0844(200006)18:2<85::AID-CBF853>3.0.CO;2-Y.
A number of studies have reported that oxidant stress reduces the activity of isolated Na(+)-K(+) ATPase and Ca(2+) ATPase which are known to affect the cell membrane integrity. The aim of the study is to determine whether the administration of lisinopril is able to protect the membrane-bound enzyme levels in isolated guinea pig hearts and also ascertain whether or not a relationship exists between oxygen free radicals and membrane bound Na(+)-K(+) ATPase and Ca(2+) ATPase. Forty guinea pig hearts were studied in an isolated Krebs-Henseleit solution-perfused Langendorff cardiac model. In all groups cardioplegic arrest was achieved by administering St. Thomas' Hospital cardioplegic solution (STHCS). Group 1 (control, n=10) received only STHCS. Group 2 (n=10) were arrested with lisinopril (l micromol l(-1)) added STHCS. Group 3 (n=10) were pretreated with oral lisinopril (0.2 mg kg(-1) twice a day) for 10 days and then arrested with STHCS. Group 4 were also pretreated with oral lisinopril (0.2 mg kg(-1) twice a day for 10 days), arrested with STHCS and reperfused with lisinopril added to Krebs-Henseleit solution (l micromol l(-1)). Hearts were subjected to normothermic global ischaemia for 90 min and then reperfused at 37 degrees C. Pretreatment and addition of lisinopril in the reperfusion buffer improved the levels of membrane-bound enzymes. When the treated groups were compared with control hearts, the best results were achieved in group 4. The Na(+)-K(+) and Ca(2+) ATPase levels increased from 466.38+/-5.99 to 560.12+/-18.02 and 884.69+/-9.13 to 1287.71+/-13.01 nmolPi mg(-1) protein h(-1) respectively (p<0.05). These results suggest that lisinopril protects the cell membrane integrity and lessens free radical-induced oxidant stress.
多项研究报告称,氧化应激会降低已知影响细胞膜完整性的离体钠钾ATP酶和钙ATP酶的活性。本研究的目的是确定给予赖诺普利是否能够保护离体豚鼠心脏中膜结合酶的水平,并确定氧自由基与膜结合的钠钾ATP酶和钙ATP酶之间是否存在关系。在离体的Krebs-Henseleit溶液灌注的Langendorff心脏模型中对40个豚鼠心脏进行了研究。在所有组中,通过给予圣托马斯医院心脏停搏液(STHCS)实现心脏停搏。第1组(对照组,n = 10)仅接受STHCS。第2组(n = 10)在加入赖诺普利(1 μmol l⁻¹)的STHCS中停搏。第3组(n = 10)口服赖诺普利(0.2 mg kg⁻¹,每天两次)预处理10天,然后用STHCS停搏。第4组也用口服赖诺普利(0.2 mg kg⁻¹,每天两次,共10天)预处理,用STHCS停搏,并在Krebs-Henseleit溶液(1 μmol l⁻¹)中加入赖诺普利进行再灌注。心脏进行90分钟的常温全心缺血,然后在37℃下再灌注。预处理以及在再灌注缓冲液中添加赖诺普利提高了膜结合酶的水平。当将治疗组与对照心脏进行比较时,第4组取得了最佳结果。钠钾ATP酶和钙ATP酶水平分别从466.38±5.99增加到560.12±18.02以及从884.69±9.13增加到1287.71±13.01 nmolPi mg⁻¹蛋白质 h⁻¹(p<0.05)。这些结果表明,赖诺普利可保护细胞膜完整性并减轻自由基诱导的氧化应激。